At a glance
ClinicalIndex Comparison Record- ✓Histologically proven hematologic malignancy including ALL in second or later remission, or first remission with poor prognostic features (Philadelphia chromosome positive)
- ✓AML in second or later remission, or first remission with poor prognostic features (arising from MDS, cytogenetics -5/-7/+8/11q23, or complex)
- ✓Myelodysplastic syndrome, chronic myelogenous leukemia, relapsed Hodgkin's disease, relapsed non-Hodgkin's lymphoma, or multiple myeloma
- ✓AML or ALL refractory to induction or in relapse
- ✕HIV antibody positive
- ✕Hepatitis B surface antigen positive
- ✕Active bacterial, viral, or fungal infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cord Blood Transplantation for Hematologic Malignancies and Bone Marrow Failure Syndromes
In Brief
A Phase 2 clinical trial evaluating anti-thymocyte globulin, filgrastim, and 7 other interventions for Graft Versus Host Disease and 4 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy, radiation therapy, and umbilical cord blood transplantation in treating patients with hematologic cancer.
Study Details
Timeline
Interventions
IV
IV
IV
IV
IV
IV
IV
IV
High energy X-rays